TB Research

Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens

Kusmiati T, Mertaniasih NM, Putranto JNE, Suprapti B, Luthfah N, Soedarsono S, Koesoemoprodjo W, Sari AP

Acta medica Indonesiana · 2022-01

Abstract

Background Drug-resistant tuberculosis (DR-TB) is a global health concern. QTc prolongation is a serious adverse effect in DR-TB patients receiving a shorter regimen. This study aimed to evaluate the correlation of moxifloxacin concentration, CRP, and inflammatory cytokines with QTc interval in DR-TB patients treated with a shorter regimen. Methods This study was performed in 2 groups of rifampicin-resistant (RR-TB) patients receiving shorter regimens. Correlation for all variables was analyzed. Results CRP, IL-1β, and QTc baseline showed significant differences between 45 RR-TB patients on intensive phase and continuation phase with p-value of Conclusion Moxifloxacin concentration, CRP, and inflammatory cytokines did not correlate with QTc interval in RR-TB patients treated with shorter regimens. The use of moxifloxacin is safe but should be routinely monitored and considered the presence of other risk factors for QTc prolongation in RR-TB patients who received shorter regimens.

MeSH terms

  • Humans
  • Tuberculosis, Multidrug-Resistant
  • Long QT Syndrome
  • Rifampin
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Interleukin-6
  • Cytokines
  • Antitubercular Agents
  • Electrocardiography
  • Moxifloxacin